Clinical Trials

608 enrolled 17 charts

Breast Neoplasms

NCT07416409 2026-02-18

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Completed

80 enrolled

Breast Neoplasms, Neoplasms

NCT02158507 2026-01-22

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Phase NA Completed

20 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01526369 2025-05-09

TH V THL

75 enrolled

Breast Neoplasms

NCT00490139 2025-03-21

ALTTO

8,381 enrolled 22 charts

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

652 enrolled 50 charts

Breast Neoplasms

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

369 enrolled 19 charts

Breast Neoplasms

NCT00470704 2024-12-19

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

87 enrolled 23 charts

Breast Neoplasms

NCT01619111 2024-06-04

DETECT III

105 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating

NCT00424164 2024-03-08

LAPATAM

20 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT01622868 2023-10-17

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

143 enrolled 24 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01138384 2023-08-04

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Phase 1/2 Completed

19 enrolled

Breast Neoplasms

NCT03084939 2023-05-06

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

351 enrolled

Breast Neoplasms

NCT00841828 2023-03-31

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

102 enrolled 10 charts

Breast Neoplasms

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

65 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

122 enrolled 22 charts

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT00952692 2021-12-20

Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer

Phase 1/2 Completed

12 enrolled 9 charts

Breast Neoplasms

NCT00444535 2021-10-25

Lapatinib and Bevacizumab for Metastatic Breast Cancer

52 enrolled 13 charts

Breast Neoplasms, Osteitis Deformans

NCT00206427 2021-09-29

GW

49 enrolled 7 charts

Breast Neoplasms, Neoplasms

NCT00553358 2021-09-21

Neo ALTTO

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

NCT01808573 2021-06-11

NALA

621 enrolled 21 charts 2 FDA

HER2+ Metastatic Breast Cancer (MBC)

NCT00073528 2021-02-24

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

1,286 enrolled 41 charts

Breast Neoplasms

NCT02650752 2021-01-26

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

11 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00367471 2020-09-09

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

31 enrolled

Phase EARLY_PHASE1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01875666 2020-09-04

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

26 enrolled

Breast Neoplasms

NCT00085020 2020-08-03

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

13 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

159 enrolled

HER2 Positive Breast Cancer

NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

64 enrolled 13 charts

Phase EARLY_PHASE1 Completed

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

NCT00331630 2020-03-06

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

30 enrolled 13 charts

Breast Neoplasms

NCT00390455 2019-12-20

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

295 enrolled 18 charts

Breast Neoplasms

NCT00263588 2019-12-12

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

242 enrolled 19 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms

NCT00820872 2019-10-21

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

30 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01434303 2019-05-20

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

37 enrolled

Breast Neoplasms

NCT02073916 2019-04-16

STELA

24 enrolled

Breast Neoplasms

NCT00820222 2019-04-02

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

540 enrolled 18 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00320411 2019-01-31

GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer

62 enrolled 24 charts

Breast Neoplasms

NCT01973660 2018-09-19

PAMELA

151 enrolled

Breast Neoplasms

NCT00477464 2018-09-17

Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

51 enrolled 25 charts

Breast Neoplasms

NCT00371488 2018-08-31

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

11 enrolled

Breast Neoplasms

NCT00462956 2018-08-31

GW572016 In Patients With Advanced Or Metastatic Breast Cancer

59 enrolled

Breast Neoplasms

NCT00777101 2018-08-09

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

233 enrolled 16 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01485926 2018-08-06

TCHL Phase II

120 enrolled

Breast Neoplasms

NCT00555152 2018-04-20

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

Phase NA Completed

22 enrolled 9 charts

Carcinoma, Intraductal, Noninfiltrating

NCT00790816 2018-02-28

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

500 enrolled

Breast Neoplasms, Neoplasms

NCT00148902 2017-12-06

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

52 enrolled

Breast Neoplasms, Neoplasms

NCT00258050 2017-12-06

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

24 enrolled

Breast Neoplasms

NCT00118157 2017-12-04

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

19 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00169533 2017-11-17

Rollover Study Of Lapatinib In Cancer Patients

31 enrolled

Breast Neoplasms

NCT00388076 2017-11-17

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

86 enrolled